The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate ...

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and ...

SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting ...

Dr Rebecca Rhee works at Maimonides Medical Center where she is a colorectal surgeon and program director of the general surgery residence.

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet ...

Proton therapy may reduce urinary, bowel and sexual side effects in prostate cancer by minimizing radiation exposure to ...

Gayle S. Jameson, M.S.N, ACNP-BC, AOCN, an oncology nurse practitioner at HonorHealth Research Institute (HRI), is a ...